الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
The research was interested in studying the impact of hepatitis C virus on pharmacokinetics of tacrolimus among renal transplant recipients with +ve HCV. Thirty renal recipients were used and divided into two equal groups, one group with +ve HCV and the other group with ve HCV. Pharmacokinetics of tacrolimus was estimated through tacrolimus trough blood levels at day0, day14, and month3 of using the therapy in different time points: predose 1, 3, 6, 12 hour postdose. Both groups were examined for Biochemistry (creatinine , fasting and postprandial blood sugar, uric acid, ALT, AST, AP, Alb, and haematology (Haemoglubin, haematocrite, count of white cells, platelets) tests. In conclusion, tacrolimus is a safe immunosuppressive agent for renal recipients with or without HCV infection and HCV has no impact on pharmacokinetics of tacrolimus.